Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 4/20 | 0.56 |
| ▸ | TOP2B | Q02880 | 4/20 | 0.56 |
| ▸ | GSK3B | P49841 | 8/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | AADAT | Q8N5Z0 | 2/20 | 0.47 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | TUBB | P07437 | 1/20 | 0.47 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.47 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.47 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.47 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.47 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.47 |
| ▸ | TUBB2A | Q13885 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2194978 | 0.91 | GSK3B (0.50) | TOP2ATOP2BGSK3BKDM4EKMT2A | |
| SCHEMBL2570884 | 0.86 | TOP2A (0.42) | TOP2ATOP2BGSK3BKDM4EKMT2A | |
| SCHEMBL1345435 | 0.86 | TOP2A (0.42) | TOP2ATOP2BGSK3BKDM4EKMT2A | |
| SCHEMBL1345437 | 0.86 | TOP2A (0.42) | TOP2ATOP2BGSK3BKDM4EKMT2A | |
| SCHEMBL2570886 | 0.86 | TOP2A (0.42) | TOP2ATOP2BGSK3BKDM4EKMT2A | |
| SCHEMBL6007708 | 0.83 | GSK3B (0.64) | TOP2ATOP2BGSK3BKDM4EKMT2A | |
| SCHEMBL6007712 | 0.83 | GSK3B (0.64) | TOP2ATOP2BGSK3BKDM4EKMT2A | |
| SCHEMBL30306157 | 0.83 | GSK3B (0.64) | TOP2ATOP2BGSK3BKDM4EKMT2A | |
| SCHEMBL10813276 | 0.82 | KDM4E (0.41) | TOP2ATOP2BGSK3BKDM4EKMT2A | |
| SCHEMBL9148784 | 0.78 | TOP2A (0.51) | TOP2ATOP2BGSK3BKDM4EKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3630779-B1 | ANTIBIOTIC RESISTANCE BREAKERS | KING S COLLEGE LONDON (GB) | 2025-09-03 | — | — | EP | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| US-11746116-B2 | Antibiotic resistance breakers | KING'S COLLEGE LONDON (GB) | 2023-09-05 | — | — | US | disclosed |
| CN-110869373-B | Antibiotic resistance disruptors | 伦敦皇家学院 | 2023-03-07 | — | — | CN | disclosed |
| US-8389514-B2 | Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-8389514-B2 | Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| US-8389514-B2 | Cyanoaminoquinolones and tetrazoloaminoquinolones as GSK-3 inhibitors | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2013-03-05 | — | — | US | disclosed |
| EP-2203458-B1 | CYANOAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN SEIYAKU KK (JP) | 2011-11-02 | — | — | EP | disclosed |
| US-20110172219-A1 | CYANOAMINOQUINOLONES AND TETRAZOLOAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172219-A1 | CYANOAMINOQUINOLONES AND TETRAZOLOAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172219-A1 | CYANOAMINOQUINOLONES AND TETRAZOLOAMINOQUINOLONES AS GSK-3 INHIBITORS | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11746116-B2 | Antibiotic resistance breakers | ABCC1, ARL1, AKR1C3 | TOP2A 1099/4885TOP2B 1046/4885GSK3B 416/4885 |
| US-20110172219-A1 | CYANOAMINOQUINOLONES AND TETRAZOLOAMINOQUINOLONES AS GSK-3 INHIBITORS | GSK3A, GSK3B, GSKIP | TOP2A 101/4885TOP2B 302/4885GSK3B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.